Additional file 1: of Impact of intrathecal morphine analgesia on the incidence of pulmonary complications after cardiac surgery: a single center propensity-matched cohort study

ICD-10 codes used to define comorbidities and outcomes and CHOP codes used to define surgical procedures. (DOCX 14 kb

Estimated mean change in weight and BMI over 4 y following bariatric surgery or no surgery.

<p>Dashed lines show 95% CIs.</p

Flow diagram of study population.

<p>Flow diagram of study population.</p

Characteristics of study population.

<p>Characteristics of study population.</p

Characteristics of study population.

<p>Characteristics of study population.</p

Association between PDE5 inhibitor use and malignant melanoma, by cumulative number of prescriptions received and time since first prescription (index date).

<p>Cumulative number of prescriptions received (top panel) and time since index date (bottom panel). From a Cox model with age timescale, stratified by matched set and adjusted for number of consultations in year before index date, BMI category, alcohol use, and smoking status.</p

Effect of PDE5 inhibitor use on malignant melanoma risk, stratified by individual-level factors.

<p>From Cox models containing interaction terms between individual-level factors and exposure (interactions fitted one at a time), with age timescale, stratified by matched set and adjusted for number of consultations in year before index date, BMI category, alcohol use, and smoking status.</p

Crude rate for malignant melanoma and control outcomes by exposure to PDE5 inhibitors, and unadjusted and adjusted hazard ratios.

<p>Crude rate for malignant melanoma and control outcomes by exposure to PDE5 inhibitors, and unadjusted and adjusted hazard ratios.</p

Graphical representation of the three different treatment stages: Users of GTZ drugs and other antidiabetic drugs classified according to first- or second-line mono- or combination therapy at the index date.

<p>For instance, to be a glitazone user in category (2), first-line non-GTZ treatment for diabetes was discontinued after 1999 when a GTZ was prescribed as second-line monotherapy. A patient could be matched to a GTZ user in category (2) if they had received an antidiabetic drug other than a GTZ (for example: Metformin) but stopped using their first-line antidiabetic treatment after 1999 and began taking another drug (for example: Sulfonylurea) as monotherapy after at least 12 months of registered follow-up.</p

IRR of PD adjusted for potential confounders.

<p>* Main analysis: IRR for the association between GTZ use and incident PD using conditional Poisson regression to control for gender, age, practice, and treatment stage</p><p>IRR of PD adjusted for potential confounders.</p